芦康沙妥珠单抗对比化疗治疗经治晚期三阴性乳腺癌的最终总生存分析
OptiTROP-Breast01 III期试验最终总生存分析显示,在经治局部复发或转移性三阴性乳腺癌患者中,芦康沙妥珠单抗(sac-TMT)对比化疗显著改善总生存,中位随访29.4个月时中位OS为14.7个月对9.9个月(HR 0.60,95%CI 0.45‒0.80),安全性无新信号。
要点
- sac-TMT较化疗显著延长经治晚期TNBC的总生存,HR 0.60。
- 敏感性分析校正后续ADC治疗后OS获益仍一致。
- 安全性特征与既往一致,未发现新安全信号。
核心结论
- 经过延长随访的最终OS分析证实,sac-TMT对比化疗在经治局部复发或转移性TNBC中具有临床意义且持续的总生存获益。
- sac-TMT的安全性特征与既往报告一致,未发现新的安全信号。
研究设计与样本
- III期OptiTROP-Breast01试验,263例经治局部复发或转移性TNBC患者按1:1随机分配至sac-TMT组(n=130)或化疗组(n=133)。
- OS为关键次要终点,本次报告为延长随访后的最终OS分析。
主要发现
- 中位随访29.4个月时,sac-TMT组中位OS为14.7个月(95%CI 12.1‒20.1),化疗组为9.9个月(95%CI 8.6‒11.8),HR 0.60(95%CI 0.45‒0.80)。
- 30个月OS率分别为26.8%和13.2%。
- 中期分析观察到的OS获益在最终分析中得以维持,且在全部亚组中总体一致。
- 化疗组27.8%的患者后续接受了抗体药物偶联物(ADC)治疗;采用秩保持结构失效时间模型校正后,sac-TMT组中位OS为14.7个月,化疗组估计为9.4个月(HR 0.55,95%CI 0.39‒0.73);删失分析结果一致(HR 0.59,95%CI 0.43-0.82)。
- 探索性患者报告结局分析显示,在全部5个评估的健康相关生活质量领域中,sac-TMT组至恶化中位时间数值上长于化疗组,疲乏和疼痛差异最大。
关键数值与推荐
- 最常见≥3级治疗相关不良事件为中性粒细胞计数降低、白细胞计数降低和贫血。
临床怎么用
- 对于经治的局部复发或转移性TNBC,sac-TMT可作为治疗选择之一,最终OS数据支持其应用。
局限性
- 化疗组部分患者后续接受ADC治疗,需采用敏感性分析方法校正后续治疗影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase 3 OptiTROP-Breast01 trial, sacituzumab tirumotecan (sac-TMT) significantly improved progression-free survival versus chemotherapy in patients with previously treated advanced triple-negative breast cancer (TNBC), with a statistically significant overall survival (OS) benefit observed at the prespecified interim OS analysis. Here we report the final OS analysis with extended follow-up. PATIENTS AND METHODS: Overall, 263 patients with previously treated locally recurrent or metastatic TNBC were randomly assigned 1:1 to sac-TMT (n=130) or chemotherapy (n=133). OS was a key secondary endpoint. RESULTS: At a median follow-up of 29.4 months, median OS was 14.7 months (95% CI 12.1‒20.1) with sac-TMT and 9.9 months (95% CI 8.6‒11.8) with chemotherapy (HR 0.60, 95% CI 0.45‒0.80); 30-month OS rates were 26.8% and 13.2%. The OS benefit observed at interim analysis was maintained at final analysis and generally consistent across all subgroups. Subsequent antibody-drug conjugate (ADC) therapy was received by 27.8% of patients in the chemotherapy group. After adjustment for subsequent ADC therapy using the rank-preserving structural failure time model, median OS was 14.7 months with sac-TMT and an estimated 9.4 months with chemotherapy (HR 0.55, 95% CI 0.39‒0.73); censoring analysis yielded consistent results (HR 0.59, 95% CI 0.43-0.82). The sac-TMT safety profile remained consistent with previous findings, with no new safety signals. The most common grade ≥3 treatment-related adverse events were decreased neutrophil count, decreased white blood cell count and anemia. Exploratory patient-reported outcome analyses showed numerically longer median time to deterioration with sac-TMT than with chemotherapy across all five evaluated health-related quality-of-life domains, with the largest differences for fatigue and pain. CONCLUSIONS: These final OS data after extended follow-up demonstrate a clinically meaningful and sustained OS benefit of sac-TMT versus chemotherapy and further reinforce its role as a treatment option for previously treated advanced TNBC. No new safety signals were identified.
引用
- Xu B, Yin Y, Fan Y, et al. Sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: final overall survival analysis of the Phase III OptiTROP-Breast01. Ann Oncol. 2026. PMID: 42933638. doi:10.1016/j.annonc.2026.10.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。